We envision a world where
DISEASES DRIVEN BY
INFLAMMATION
are treatable at their source
NodThera is leading the NLRP3 inflammasome space with its best-in-class molecules and a wealth of pre-clinical and clinical data that is setting the tone for the field. NodThera has the potential to drive a positive and meaningful difference to the lives of patients suffering with obesity, cardiometabolic and neurodegenerative diseases.
Dan Swisher, MBA
Chief Executive Officer
Meet the experts
The NodThera team is led by masters of their craft – industry leaders with the right mix of creativity, imagination, skill and expertise that will bring the potential of NLRP3-targeting medicines to life.